(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT), which develops treatments for gastrointestinal diseases, on Tuesday announced that it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) tablets for Eosinophilic Esophagitis in adults.
Eosinophilic esophagitis (EoE) is a chronic immune condition of the esophagus where white blood cells called eosinophils build up in the lining, causing inflammation, painful swallowing, choking, and food impaction.
VOQUEZNA (vonoprazan) is a potassium-competitive acid blocker (PCAB) approved by the FDA for adults for the treatment of erosive esophagitis (EE) associated with GERD, relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD), and the treatment of Helicobacter pylori (H. pylori) infection in combination with antibiotics.
The pHalcon-EoE-201 study is a two-part, randomized, double-blind, placebo-controlled Phase 2 study. In Part 1, 95 adults with endoscopically confirmed EoE and dysphagia have been randomised evenly to receive VOQUEZNA 20 mg or placebo once daily for 12 weeks. This is a large, placebo-controlled clinical trial of an acid-suppression treatment in EoE, said Phathom.
Patients who complete Part 1 are eligible to enter Part 2, a 12-week extension phase in which all participants receive VOQUEZNA 20 mg once daily.
Topline results are anticipated in the fourth quarter of 2026.
If the Phase 2 Phathom-EoE-201 study yields positive results, Phathom expects to discuss potential future development plans for EoE with the FDA, including pediatric evaluation.
PHAT has traded between $7.61 and $18.31 over the last year. PHAT is currently up 0.94% at $10.78.
For More Such Biotech Stock News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
